Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
Latest Information Update: 22 Feb 2024
Price :
$35 *
At a glance
- Drugs Mazdutide (Primary)
- Indications Hyperuricaemia; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Innovent Biologics
- 18 Feb 2024 Status changed from recruiting to completed.
- 18 May 2023 Status changed from not yet recruiting to recruiting.
- 03 Apr 2023 New trial record